Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy
Emergent BioSolutions was awarded a $64.5 million contract modification from the U.S. Department of Health and Human Services for its BAT botulism antitoxin. The modification extends an existing 10-year contract with the Administration for Strategic Preparedness and Response (ASPR) to supply the antitoxin for biodefense preparedness. This win reinforces Emergent’s role as a key supplier of medical countermeasures to the U.S.
Key figures
- Deal Value Usd
- 64500000
- Contract duration
- 10-year
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.